This table (“dashboard”) shows the applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.
On this page you’ll find answers to frequently asked questions about mRNA vaccines.
All about the vaccines - briefly and concisely explained
Vaccines: Rapid solution for new diseases?
Swismedic - The way a vaccination works
How an mRNA vaccine works
How a vector vaccine works?
How a protein vaccine works
How is the safety of vaccines monitored?
Communication regarding COVID-19
Application submitted for Comirnaty Original/Omicron BA.4-5
Swissmedic authorises indication extension and booster
Swissmedic reviews Pfizer Schweiz AG application for Comirnaty®
Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3
Moderna's Spikevax Bivalent Original/Omicron (mRNA-1273.214) authorised from age 18
15,781 reports of suspected adverse vaccination reactions evaluated
Extended shelf live at ultra-low temperature
Beschluss Vorschriften SBSC – Blutstammzellspende
Comirnaty: Swissmedic starts rolling review of a bivalent COVID-19 vaccine
Filing of Submission Plans to evaluate the efficacy of existing COVID-19 medicinal products against new SARS-Cov-2 variants